Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2980247/0/en/MaxCyte-Celebrates-25-Years-of-Innovation-Driving-Cell-Engineering-Based-Therapeutics.html
06 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/06/2976071/0/en/MaxCyte-Reports-Third-Quarter-2024-Financial-Results-and-Updates-Full-Year-2024-Guidance.html
06 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/06/2976038/0/en/MaxCyte-Reports-Third-Quarter-2024-Financial-Results-and-Updates-Full-Year-2024-Guidance.html
31 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/31/2972591/0/en/MaxCyte-to-Participate-in-Two-Upcoming-Investor-Conferences.html
15 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/15/2963168/0/en/MaxCyte-Appoints-Cynthia-Collins-to-its-Board-of-Directors.html
11 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/11/2961986/0/en/MaxCyte-to-Report-Third-Quarter-2024-Financial-Results-on-November-6-2024.html
Details:
Be Bio gains non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of its BCMs programs.
Lead Product(s): B Cell-based Therapy
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Be Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 02, 2024
Lead Product(s) : B Cell-based Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Be Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
MaxCyte Signs License with Be Biopharma for Engineered B Cell Medicines
Details : Be Bio gains non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of its BCMs programs.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 02, 2024
Details:
Wugen gains non-exclusive clinical and commercial rights to MaxCyte’s Flow Electroporation® technology to support programs like WU-CART-007 for hematologic and solid tumors.
Lead Product(s): WU-CART-007
Therapeutic Area: Oncology Brand Name: WU-CART-007
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Wugen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 30, 2024
Lead Product(s) : WU-CART-007
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Wugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte and Wugen Sign License to Expedite Manufacturing of Cell Therapies for Cancer
Details : Wugen gains non-exclusive clinical and commercial rights to MaxCyte’s Flow Electroporation® technology to support programs like WU-CART-007 for hematologic and solid tumors.
Brand Name : WU-CART-007
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 30, 2024
Details:
Imugene has obtained commercial rights to use MaxCyte’s technology and ExPERT platform to support azer-cel, a potential allogeneic CD19 CAR T product candidate for blood cancer treatment.
Lead Product(s): Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Brand Name: PBCAR0191
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Imugene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Imugene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte Signs License with Imugene To Advance Cancer Immunotherapy Programs
Details : Imugene has obtained commercial rights to use MaxCyte’s technology and ExPERT platform to support azer-cel, a potential allogeneic CD19 CAR T product candidate for blood cancer treatment.
Brand Name : PBCAR0191
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 23, 2024
Details:
Under the agreement, Lion TCR obtains worldwide non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for developing new TCR-T cell therapies for solid tumors.
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Cell and Gene therapy
Sponsor: Lion TCR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2024
Lead Product(s) : TCR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Lion TCR
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte and Lion TCR Partner To Expand TCR-T Cell Pipeline Globally
Details : Under the agreement, Lion TCR obtains worldwide non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for developing new TCR-T cell therapies for solid tumors.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2024
Details:
Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapies.
Lead Product(s): Genetic Therapy
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Cell and Gene therapy
Sponsor: Prime Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023
Lead Product(s) : Genetic Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Prime Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapi...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 01, 2023
Details:
Vittoria will obtain rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform which will support its Senza5 technology to enhance efficacy of T-cell therapies including, Viper 101, a gene-edited, autologous, dual-population cell therapy for T-cell lymphoma.
Lead Product(s): Viper 101
Therapeutic Area: Oncology Brand Name: Viper 101
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Vittoria Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Lead Product(s) : Viper 101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Vittoria Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Vittoria will obtain rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform which will support its Senza5 technology to enhance efficacy of T-cell therapies including, Viper 101, a gene-edited, autologous, dual-population cell ther...
Brand Name : Viper 101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 10, 2023
Details:
Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.
Lead Product(s): B Cell-based Therapeutic
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Cell and Gene therapy
Sponsor: Walking Fish Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2023
Lead Product(s) : B Cell-based Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Walking Fish Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 04, 2023
Details:
CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalable manufacturing.
Lead Product(s): CAR-NK Cell Therapy
Therapeutic Area: Oncology Brand Name: CAT-248
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Catamaran Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2023
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Catamaran Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalabl...
Brand Name : CAT-248
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2023
Details:
Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Cell and Gene therapy
Sponsor: Curamys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Curamys
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 05, 2022
Details:
Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly known as CTX001).
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Genetic Disease Brand Name: Exa-cel
Study Phase: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Vertex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 28, 2022
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly k...
Brand Name : Exa-cel
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 28, 2022
ABOUT THIS PAGE
MaxCyte is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Raw materials for cell processing, etc.-MaxCyte ExPERTTM GTx Flow Transfection System bulk with JDMF offered by MaxCyte
LOOKING FOR A SUPPLIER?